291 related articles for article (PubMed ID: 26194532)
1. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
[TBL] [Abstract][Full Text] [Related]
2. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.
Elgindy EA; El-Haieg DO; Khorshid OM; Ismail EI; Abdelgawad M; Sallam HN; Abou-Setta AM
Obstet Gynecol; 2013 Jan; 121(1):78-86. PubMed ID: 23262931
[TBL] [Abstract][Full Text] [Related]
3. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
4. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
5. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
7. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-Releasing Hormone Analogs for Gonadal Protection During Gonadotoxic Chemotherapy: A Systematic Review and Meta-Analysis.
Sofiyeva N; Siepmann T; Barlinn K; Seli E; Ata B
Reprod Sci; 2019 Jul; 26(7):939-953. PubMed ID: 30270741
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
Marder W; McCune WJ; Wang L; Wing JJ; Fisseha S; McConnell DS; Christman GM; Somers EC
Gynecol Endocrinol; 2012 Aug; 28(8):624-7. PubMed ID: 22296584
[TBL] [Abstract][Full Text] [Related]
10. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
[TBL] [Abstract][Full Text] [Related]
11. Regulation of AMH and SCF expression in human granulosa cells by GnRH agonist and antagonist.
Dong M; Huang L; Wang W; Du M; He Z; Mo Y; Yang D
Pharmazie; 2011 Jun; 66(6):436-9. PubMed ID: 21699083
[TBL] [Abstract][Full Text] [Related]
12. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
13. An assessment of the protective effect of gonadotropin-releasing hormone agonist and antagonist on bleomycin-induced ovarian toxicity in rats.
Atakul T; Tayyar AT; Turan ÖD; Çelik SY; Yılmaz M; Küçük M; Yüksel H; Demirci B
Gynecol Endocrinol; 2021 Jan; 37(1):46-50. PubMed ID: 32283955
[TBL] [Abstract][Full Text] [Related]
14. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.
Li X; Kang X; Deng Q; Cai J; Wang Z
Reprod Biol Endocrinol; 2013 Mar; 11():16. PubMed ID: 23452939
[TBL] [Abstract][Full Text] [Related]
15. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
16. [Role of GnRH agonists in preserving female fertility].
Thomin A; Torre A; Daraï É; Chabbert-Buffet N
J Gynecol Obstet Biol Reprod (Paris); 2014 Apr; 43(4):267-74. PubMed ID: 24321862
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
18. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues.
Huser M; Smardova L; Janku P; Crha I; Zakova J; Stourac P; Jarkovsky J; Mayer J; Ventruba P
J Assist Reprod Genet; 2015 Aug; 32(8):1187-93. PubMed ID: 25724588
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
20. Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model.
Horicks F; Van Den Steen G; Houben S; Englert Y; Demeestere I
PLoS One; 2015; 10(9):e0137164. PubMed ID: 26325271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
